Fibrinogen to pre-albumin ratio is an independent prognostic index for patients with pancreatic ductal adenocarcinoma after radical resection.
Fibrinogen to pre-albumin ratio
Overall survival
Pancreatic cancer
Prognosis
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
28 Oct 2024
28 Oct 2024
Historique:
received:
10
05
2024
accepted:
01
09
2024
medline:
29
10
2024
pubmed:
29
10
2024
entrez:
29
10
2024
Statut:
epublish
Résumé
This study aims to elucidate the significance of the preoperative fibrinogen to pre-albumin ratio (FPR) in predicting the prognosis of pancreatic ductal adenocarcinoma (PDAC), a correlation not extensively explored previously. A cohort of 563 patients diagnosed with PDAC and subjected to radical surgical resection was examined. We meticulously documented a range of inflammatory markers, clinical-pathological features, and oncological outcomes. The prognostic value of preoperative FPR was assessed using Kaplan-Meier survival analysis and Cox proportional hazards regression modeling. Furthermore, the predictive accuracy of FPR was evaluated through time-dependent receiver operating characteristic (ROC) curves and decision curve analyses (DCA). The determined optimal threshold for FPR was 14.77, which facilitated the stratification of patients into groups with low and high FPR levels. Notably, patients in the high FPR cohort exhibited significantly reduced recurrence-free survival (RFS) and overall survival (OS) rates compared to their low FPR counterparts. Multivariate Cox regression analysis underscored FPR as an independent prognostic indicator for both RFS and OS. In comparison to the neutrophil-to-lymphocyte ratio (NLR), FPR demonstrated superior prognostic accuracy and clinical utility. The preoperative fibrinogen to pre-albumin ratio serves as an independent prognostic marker for RFS and OS among PDAC patients undergoing radical resection. Our findings suggest that FPR could be a valuable addition to the current prognostic models, potentially guiding therapeutic decision-making and patient management strategies in PDAC.
Sections du résumé
BACKGROUND
BACKGROUND
This study aims to elucidate the significance of the preoperative fibrinogen to pre-albumin ratio (FPR) in predicting the prognosis of pancreatic ductal adenocarcinoma (PDAC), a correlation not extensively explored previously.
METHODS
METHODS
A cohort of 563 patients diagnosed with PDAC and subjected to radical surgical resection was examined. We meticulously documented a range of inflammatory markers, clinical-pathological features, and oncological outcomes. The prognostic value of preoperative FPR was assessed using Kaplan-Meier survival analysis and Cox proportional hazards regression modeling. Furthermore, the predictive accuracy of FPR was evaluated through time-dependent receiver operating characteristic (ROC) curves and decision curve analyses (DCA).
RESULTS
RESULTS
The determined optimal threshold for FPR was 14.77, which facilitated the stratification of patients into groups with low and high FPR levels. Notably, patients in the high FPR cohort exhibited significantly reduced recurrence-free survival (RFS) and overall survival (OS) rates compared to their low FPR counterparts. Multivariate Cox regression analysis underscored FPR as an independent prognostic indicator for both RFS and OS. In comparison to the neutrophil-to-lymphocyte ratio (NLR), FPR demonstrated superior prognostic accuracy and clinical utility.
CONCLUSION
CONCLUSIONS
The preoperative fibrinogen to pre-albumin ratio serves as an independent prognostic marker for RFS and OS among PDAC patients undergoing radical resection. Our findings suggest that FPR could be a valuable addition to the current prognostic models, potentially guiding therapeutic decision-making and patient management strategies in PDAC.
Identifiants
pubmed: 39468569
doi: 10.1186/s12957-024-03524-0
pii: 10.1186/s12957-024-03524-0
doi:
Substances chimiques
Fibrinogen
9001-32-5
Biomarkers, Tumor
0
Prealbumin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
284Informations de copyright
© 2024. The Author(s).
Références
Ilic I, Ilic M. International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: A joinpoint regression analysis. World J Gastroenterol. 2022;28:4698–715.
doi: 10.3748/wjg.v28.i32.4698
pubmed: 36157927
pmcid: 9476884
Stoffel EM, Brand RE, Goggins M. Pancreatic Cancer: Changing Epidemiology and New Approaches to Risk Assessment, Early Detection, and Prevention. Gastroenterology. 2023;164:752–65.
doi: 10.1053/j.gastro.2023.02.012
pubmed: 36804602
Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH, Weiss MJ, Zheng L, Wolfgang CL, He J. Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Ann Surg. 2018;267:936–45.
doi: 10.1097/SLA.0000000000002234
pubmed: 28338509
Blackford AL, Canto MI, Klein AP, Hruban RH, Goggins M. Recent Trends in the Incidence and Survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results Analysis. J Natl Cancer Inst. 2020;112:1162–9.
doi: 10.1093/jnci/djaa004
pubmed: 31958122
pmcid: 7669234
Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018;379:2395–406.
doi: 10.1056/NEJMoa1809775
pubmed: 30575490
Zhou Y, Wei Q, Fan J, Cheng S, Ding W, Hua Z. Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: A meta-analysis containing 8252 patients. Clin Chim Acta. 2018;479:181–9.
doi: 10.1016/j.cca.2018.01.024
pubmed: 29407690
Zhou Y, Cheng S, Fathy AH, Qian H, Zhao Y. Prognostic value of platelet-to-lymphocyte ratio in pancreatic cancer: a comprehensive meta-analysis of 17 cohort studies. Onco Targets Ther. 2018;11:1899–908.
doi: 10.2147/OTT.S154162
pubmed: 29670365
pmcid: 5896656
Vujic J, Marsoner K, Wienerroither V, Mischinger HJ, Kornprat P. The Predictive Value of the CRP-to-Albumin Ratio for Patients With Pancreatic Cancer After Curative Resection: A Retrospective Single Center Study. In Vivo. 2019;33:2071–8.
doi: 10.21873/invivo.11706
pubmed: 31662540
pmcid: 6899080
Fang L, Yan FH, Liu C, Chen J, Wang D, Zhang CH, Lou CJ, Lian J, Yao Y, Wang BJ, et al. Systemic Inflammatory Biomarkers, Especially Fibrinogen to Albumin Ratio, Predict Prognosis in Patients with Pancreatic Cancer. Cancer Res Treat. 2021;53:131–9.
doi: 10.4143/crt.2020.330
pubmed: 32854494
Perisanidis C, Psyrri A, Cohen EE, Engelmann J, Heinze G, Perisanidis B, Stift A, Filipits M, Kornek G, Nkenke E. Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: A systematic review and meta-analysis. Cancer Treat Rev. 2015;41:960–70.
doi: 10.1016/j.ctrv.2015.10.002
pubmed: 26604093
Smith SH. Using albumin and prealbumin to assess nutritional status. Nursing. 2017;47:65–6.
doi: 10.1097/01.NURSE.0000511805.83334.df
pubmed: 28328780
Liang Y, Guo H, Man Q, Chang S, Wang E, Gao S. Prognostic nutritional score based on pretreatment lymphocyte, platelet, and prealbumin predicts prognosis in patients with pancreatic cancer. J Surg Oncol. 2023;128:831–43.
doi: 10.1002/jso.27362
pubmed: 37243944
Li H, Sun Y, Wang C, Xue Y. Prognostic Value of Fibrinogen to Prealbumin Ratio (FPR) in Resectable Gastric Cancer. J Inflamm Res. 2024;17:1325–35.
doi: 10.2147/JIR.S440832
pubmed: 38434582
pmcid: 10908278
Li B, Deng H, Zhou Z, Tang B. The Prognostic value of the Fibrinogen to pre-albumin ratio in malignant tumors of the digestive system: a systematic review and meta-analysis. Cancer Cell Int. 2022;22:22.
doi: 10.1186/s12935-022-02445-w
pubmed: 35033080
pmcid: 8760749
Alifano M, Mansuet-Lupo A, Lococo F, Roche N, Bobbio A, Canny E, Schussler O, Dermine H, Régnard JF, Burroni B, et al. Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome of resected non-small cell lung cancer. PLoS ONE. 2014;9: e106914.
doi: 10.1371/journal.pone.0106914
pubmed: 25238252
pmcid: 4169516
Shu YJ, Weng H, Bao RF, Wu XS, Ding Q, Cao Y, Wang XA, Zhang F, Xiang SS, Li HF, et al. Clinical and prognostic significance of preoperative plasma hyperfibrinogenemia in gallbladder cancer patients following surgical resection: a retrospective and in vitro study. BMC Cancer. 2014;14:566.
doi: 10.1186/1471-2407-14-566
pubmed: 25096189
pmcid: 4131047
Zheng S, Shen J, Jiao Y, Liu Y, Zhang C, Wei M, Hao S, Zeng X. Platelets and fibrinogen facilitate each other in protecting tumor cells from natural killer cytotoxicity. Cancer Sci. 2009;100:859–65.
doi: 10.1111/j.1349-7006.2009.01115.x
pubmed: 19302289
pmcid: 11158185
Shen Q, Liu W, Quan H, Pan S, Li S, Zhou T, Ouyang Y, Xiao H. Prealbumin and lymphocyte-based prognostic score, a new tool for predicting long-term survival after curative resection of stage II/III gastric cancer. Br J Nutr. 2018;120:1359–69.
doi: 10.1017/S0007114518002854
pubmed: 30370885
Cai W, Kong W, Dong B, Zhang J, Chen Y, Xue W, Huang Y, Zhou L, Huang J. Pretreatment Serum Prealbumin as an Independent Prognostic Indicator in Patients With Metastatic Renal Cell Carcinoma Using Tyrosine Kinase Inhibitors as First-Line Target Therapy. Clin Genitourin Cancer. 2017;15:e437–46.
doi: 10.1016/j.clgc.2017.01.008
pubmed: 28188047
Kawai H, Ota H. Low perioperative serum prealbumin predicts early recurrence after curative pulmonary resection for non-small-cell lung cancer. World J Surg. 2012;36:2853–7.
doi: 10.1007/s00268-012-1766-y
pubmed: 22948197
Li C, Fan Z, Guo W, Liang F, Mao X, Wu J, Wang H, Xu J, Wu D, Liu H, et al. Fibrinogen-to-prealbumin ratio: A new prognostic marker of resectable pancreatic cancer. Front Oncol. 2023;13:1149942.
doi: 10.3389/fonc.2023.1149942
pubmed: 37051547
pmcid: 10083287
Chen C, Liu Y, Han P, Cui B. Research Progress of Preoperative FPR, FAR or AFR in Patients with Colorectal Cancer. Cancer Manag Res. 2021;13:1791–801.
doi: 10.2147/CMAR.S292605
pubmed: 33654428
pmcid: 7910077
Gugenheim J, Crovetto A, Petrucciani N. Neoadjuvant therapy for pancreatic cancer. Updates Surg. 2022;74:35–42.
doi: 10.1007/s13304-021-01186-1
pubmed: 34628591